Forbion’s record €2.3 billion fundraising backs two new funds
STAT reports on Forbion’s €2.3 billion ($2.6 billion) fundraise, its largest to date. Raised across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, the new capital brings Forbion’s assets under management to approximately €7.5 billion.
Together, the funds provide capacity to support around 30 biotech companies. Growth Opportunities Fund IV focuses on later-stage biopharma companies, while Ventures Fund VIII backs therapeutics-focused biotech companies, including existing businesses and new ventures built around promising science and experienced teams.
The fundraising reflects Forbion’s continued commitment to investing selectively across the life sciences, applying its experience and strategy to support companies developing important medicines.